## Karim J Halazun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6688456/publications.pdf

Version: 2024-02-01

293460 214428 2,996 54 24 citations h-index papers

g-index 54 54 54 4520 docs citations times ranked citing authors all docs

50

#	Article	IF	CITATIONS
1	Offer Acceptance Patterns for Liver Donors Aged 70 and Older. Liver Transplantation, 2022, 28, 571-580.	1.3	4
2	Are Current National Review Board Downstaging Protocols for Hepatocellular Carcinoma Too Restrictive?. Journal of the American College of Surgeons, 2022, 234, 579-588.	0.2	2
3	Development and validation of a deep learning model for the prediction of hepatocellular cancer recurrence after transplantation: An international study. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S71-S71.	0.1	О
4	RAPIDâ€ly Increasing the Availability of Livers?. Liver Transplantation, 2021, 27, 489-490.	1.3	1
5	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 2021, 232, 361-371.	0.2	23
6	Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non–Hepatocellular Carcinoma Factors. Liver Transplantation, 2021, 27, 684-698.	1.3	3
7	SARSâ€CoVâ€2 infection increases tacrolimus concentrations in solidâ€organ transplant recipients. Clinical Transplantation, 2021, 35, e14193.	0.8	14
8	Dynamic $\hat{l}_{\pm}$ -Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surgery, 2021, 156, 559.	2.2	34
9	Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization. Clinical Imaging, 2021, 80, 117-122.	0.8	4
10	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA Surgery, 2021, 156, e213112.	2.2	30
11	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology and Hepatology, 2021, 6, 933-946.	3.7	73
12	Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 2020, 271, 616-624.	2.1	65
13	Ex Vivo Resection and Autotransplantation for Conventionally Unresectable Tumors – An 11-year Single Center Experience. Annals of Surgery, 2020, 272, 766-772.	2.1	19
14	Liver transplantation and hepatobiliary surgery in 2020. International Journal of Surgery, 2020, 82, 1-3.	1.1	4
15	Living Donor Liver Transplant: Send in the Robots. Liver Transplantation, 2020, 26, 1393-1394.	1.3	1
16	Expanding the donor pool for liver transplantation with marginal donors. International Journal of Surgery, 2020, 82, 30-35.	1.1	38
17	Robotic liver resection: Hurdles and beyond. International Journal of Surgery, 2020, 82, 155-162.	1.1	36
18	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West–East Collaborative Effort. Cancers, 2020, 12, 452.	1.7	20

#	Article	IF	CITATIONS
19	Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology, 2020, 72, 2014-2028.	3.6	68
20	Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A) Tj ETQq0 0 0 rgBT	/Oyerlock	10 Tf 50 702
21	Lest we forget. American Journal of Transplantation, 2020, 20, 1785-1786.	2.6	12
22	An international multicenter study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise. Journal of Hepatology, 2020, 73, 873-881.	1.8	22
23	Whose Liver Is It Anyway? Two Centers Participating in One Living Donor Transplantation. Liver Transplantation, 2019, 25, 1710-1713.	1.3	5
24	Striving for decreased post-transplant hepatocellular carcinoma recurrence without excluding potentially curable patients: the utility of tumor biology. Hepatobiliary Surgery and Nutrition, 2019, 8, 541-542.	0.7	0
25	Liver transplantation for colorectal liver metastasis. Current Opinion in Organ Transplantation, 2019, 24, 175-181.	0.8	14
26	No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Annals of Surgery, 2019, 269, 20-27.	2.1	96
27	Predicting Liver Allograft Discard. Transplantation, 2018, 102, 1520-1529.	0.5	29
28	Use of robotics in liver donor right hepatectomy. Hepatobiliary Surgery and Nutrition, 2018, 7, 231-232.	0.7	11
29	Liver Transplantation for HCC Beyond Milan. Current Transplantation Reports, 2018, 5, 319-326.	0.9	2
30	Pure Laparoscopic Donor Hepatectomies. Annals of Surgery, 2018, 268, 602-609.	2.1	46
31	Is it Time to Abandon the Milan Criteria?. Annals of Surgery, 2018, 268, 690-699.	2.1	87
32	Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 17-28.	1.8	53
33	Poor outcomes for children on the wait list at low-volume kidney transplant centers in the United States. Pediatric Nephrology, 2017, 32, 669-678.	0.9	11
34	Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 2017, 265, 557-564.	2.1	204
35	Fineâ€Needle Aspiration Cytology of Pancreatic Schwannoma. Diagnostic Cytopathology, 2017, 45, 668-670.	0.5	5
36	Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation. Annals of Surgery, 2017, 266, 525-535.	2.1	131

#	Article	lF	CITATIONS
37	Expanding the Margins. Annals of Surgery, 2017, 266, 441-449.	2.1	45
38	Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation. Translational Gastroenterology and Hepatology, 2017, 2, 95-95.	1.5	8
39	Leaning to the Left. Annals of Surgery, 2016, 264, 448-456.	2.1	45
40	Reply. Hepatology, 2015, 61, 1439-1439.	3.6	0
41	Reply. Hepatology, 2015, 62, 1328-1329.	3.6	0
42	Fully laparoscopic leftâ€sided donor hepatectomy is safe and associated with shorter hospital stay and earlier return to work: A comparative study. Liver Transplantation, 2015, 21, 768-773.	1.3	68
43	Survival Benefit of Solid-Organ Transplant in the United States. JAMA Surgery, 2015, 150, 252.	2.2	414
44	Pediatric Liver Transplant Center Volume and the Likelihood of Transplantation. Pediatrics, 2015, 136, e99-e107.	1.0	44
45	Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology, 2014, 60, 1957-1962.	3.6	110
46	Diabetes, Body Mass Index, and Outcomes in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation. Transplantation, 2012, 94, 539-543.	0.5	63
47	Smoking and hepatocellular carcinoma mortality. Experimental and Therapeutic Medicine, 2012, 3, 124-128.	0.8	11
48	Do Preoperative Inflammatory Markers Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma?. Annals of Surgery, 2011, 254, 383-384.	2.1	2
49	Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer. Annals of Surgical Oncology, 2011, 18, 3362-3369.	0.7	301
50	Obesity and Microvascular Invasion in Hepatocellular Carcinoma. Cancer Investigation, 2010, 28, 1063-1069.	0.6	25
51	Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome After Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 2009, 250, 141-151.	2.1	351
52	The Combined Organ Effect. Annals of Surgery, 2008, 248, 871-879.	2.1	102
53	Preoperative Prognostic Score for Predicting Survival After Hepatic Resection for Colorectal Liver Metastases. Annals of Surgery, 2007, 246, 806-814.	2.1	179
54	Right Hepatic Trisectionectomy for Hepatobiliary Diseases. Annals of Surgery, 2007, 246, 1065-1074.	2.1	43